Almac Group gets £2m R&D grant to boost Enzyme Discovery

Professor Tom Moody, VP Technology Development and Commercialisation, Almac Sciences and Stefan Mix, Head of Biocatalysis, Almac SciencesProfessor Tom Moody, VP Technology Development and Commercialisation, Almac Sciences and Stefan Mix, Head of Biocatalysis, Almac Sciences
Professor Tom Moody, VP Technology Development and Commercialisation, Almac Sciences and Stefan Mix, Head of Biocatalysis, Almac Sciences
Almac Sciences, a member of the Almac Group, has secured £2million of support from Invest Northern Ireland to accelerate a programme of enzyme research.

Based in Craigavon, Almac Sciences had previously established a cutting-edge biotechnology platform for enzyme chemistry and biology through two successfully completed rounds of R&D investment supported by Invest NI.

This investment in R&D, awarded by INI and supported by the European Regional Development Fund, will further develop the program to establish IN Silico Informed metaGenomic Harvesting Technology (INSIGHT™), a platform built from multi-disciplinary research bringing together computational, metagenomics, biology and chemistry methodologies.

Hide Ad
Hide Ad

Routes of synthesis for most drugs are amenable to biocatalytic intervention. The INSIGHT project aims to improve the enzyme discovery process to allow more robust enzymes to supersede multi-step chemical routes currently used to produce pharmaceutical intermediates and products.

The unique project involves the development of an enzyme identification platform based around the exploitation of Almac’s existing metagenomic data mining using enzyme modelling / engineered lead diversity screening married with the company’s strength on industrial focus. This combination approach has never been developed to accelerate enzyme discovery and their subsequent application in the past and is a significant research and development programme.

This new technology will bring significant benefit to, not only Almac, but also to the wider pharmaceutical industry as it will offer simpler, lower cost and less polluting enzymatic processes. Specifically, INSIGHT will deliver new, best-in-class metagenomics, computational and engineering platforms for the pharmaceutical, biotechnology, life sciences and fine chemicals sectors.

Dr Stefan Mix, Almac Sciences’ Head of Biocatalysis, will lead a team of experts to complete the project and deliver the foundations for future commercialisation. The INSIGHT project will span six work packages which will run over 36 months once recruitment has been secured.

Hide Ad
Hide Ad

Professor Tom Moody, VP Technology Development and Commercialisation, Almac Sciences and Arran Chemical Company said: “This project, and the related INI support, will be vital to ensure we can achieve our aspiration of becoming a global leader in biotechnology. The ambitious project will bring together each of the critical elements to accelerate enzyme identification and discovery and will de-risk the enzyme development pipelines for Almac. As a result of this unique project there will be both major academic and commercial benefits, providing significant growth opportunity for the NI Bio-economy and the wider economy.”

Kevin Holland, CEO of Invest NI added: “Almac has long been one of Northern Ireland’s most successful companies within our thriving life and health sciences sector and has worked hard to build an impressive global reputation for ground-breaking work in the global pharmaceutical industry. It recognises the benefits of investing in cutting edge R&D and is making this new investment to build upon the foundations from previous R&D and capital investment over the last number of years.

“Invest NI has developed a strong collaborative partnership with Almac over the years, offering support for job creation and highly successful R&D projects. Our £2million ERDF funded offer of support for this new investment will further cement the company’s world-renowned reputation and enable it to expand its biocatalysis capability creating a new, greener and more cost-effective solution to industry. The development of this new technology enhances Northern Ireland’s global reputation in the field.”

Invest NI’s R&D support is part financed by the European Regional Development Fund under the EU investment for Growth and Jobs Programme 2014-2020.

A message from the Editor:

Hide Ad
Hide Ad

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

In order for us to continue to provide high quality and trusted local news on this free-to-read site, I am asking you to also please purchase a copy of our newspaper whenever you are able to do so.

Our journalists are highly trained and our content is independently regulated by IPSO to some of the most rigorous standards in the world. But being your eyes and ears comes at a price. So we need your support more than ever to buy our newspapers during this crisis.

With the coronavirus lockdown having a major impact on many of our local valued advertisers - and consequently the advertising that we receive - we are more reliant than ever on you helping us to provide you with news and information by buying a copy of our newspaper when you can safely.

Hide Ad
Hide Ad

You can also enjoy unlimited access to the best news from across Northern Ireland and the UK by subscribing to newsletter.co.uk

With a digital subscription, you can read more than five articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit https://www.newsletter.co.uk/subscriptions now to sign up.

Thank you

Related topics: